The study will assess the vaccine candidate’s safety and efficacy against Covid-19. Credit: fernando zhiminaicela from Pixabay.

UK-based gene and cell therapy group Oxford BioMedica has become part of a consortium focussed on the development, scale-up and production of a Covid-19 coronavirus vaccine candidate.

Led by Jenner Institute, University of Oxford, the consortium involves the Vaccines Manufacturing and Innovation Centre (VMIC), Cobra Biologics, Pall Life Sciences and Halix.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Vaccine ChAdOx1 nCov-19, studied in a trial in the UK, will assess vaccine candidate’s safety and ability to induce an immune response against the novel coronavirus.

Based on ChAdOx1 adenoviral vector technology developed at the Jenner Institute, the vaccine candidate was able to induce a strong immune response from one dose in preclinical and clinical trials to date.

The Jenner Institute and the Oxford Vaccine Group enrolled participants aged 18-55 years from the Thames Valley area in the country, designed to involve up to 510 participants.

As part of the alliance, the consortium will have access to Oxford Biomedica’s manufacturing facilities for viral vectors, including the new Oxbox facility.

The company, as well as other consortium manufacturing partners in the country and internationally, are set to enable scale-up of manufacturing capacity, following successful clinical trials.

Oxford Biomedica CEO John Dawson said: “While our current activities on this vaccine candidate are just initiating, should the consortium confirm there is promise for this candidate in the clinical trial initiating this month, we will play our role within the consortium to scale up manufacturing as fast as possible.

“This will help to provide significant access to the vaccine candidate for further clinical trials and potentially, if approved for use, for many people in the UK and beyond.”